
Dr. Hyung L. Kim discusses how the addition of cytoreductive nephrectomy to ICI therapy may affect survival and quality of life those with kidney cancer.
Kim currently holds various positions at Cedars-Sinai, Urology, located in Los Angeles, including professor; associate director, Urology Residency Training Program; chair, Department of Urology; co-medical director, Urologic Oncology Center; and director, Academic Urology Program. He also serves as the associate director of Surgical Research, as well as the Homer and Gloria Harvey Family Chair in Urologic Oncology in honor of Stuart Friedman, MD.